Saltar al contenido
Merck

Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis.

Pediatric blood & cancer (2013-11-26)
Amy E Armstrong, Jamie Dargart, Jennifer Reichek, David O Walterhouse, Debora Matossian, Richard A Cohn, Yasmin Gosiengfiao
RESUMEN

Renal failure is a rare complication of neuroblastoma or its therapy. To our knowledge, no reports describe treatment of children with neuroblastoma with chemotherapy in the setting of renal failure and maintenance hemodialysis. We report a 6-year-old child with high-risk neuroblastoma who developed renal failure requiring long-term hemodialysis. She was subsequently treated with 13 cycles of intravenous irinotecan 20 mg/m(2)/day and oral temozolomide 100 mg/m(2)/day for 5 days before disease progression without any dose adjustments, transfusions, febrile neutropenia or diarrhea. This case demonstrates that irinotecan and temozolomide can be safely administered in children with renal failure requiring hemodialysis.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Temozolomida, ≥98% (HPLC)
Sigma-Aldrich
Irinotecan hydrochloride, topoisomerase inhibitor
Sigma-Aldrich
7-Ethyl-10-hydroxycamptothecin, ≥98% (HPLC), powder
Supelco
Temozolomida, VETRANAL®, analytical standard